GLENMARK PHARMACEUTICALS
Back to Cashflow Statement
|
GLENMARK PHARMACEUTICALS Last 5 Year Cash Flow from Financing Activities History
[Consolidated]
| Mar2026 | Mar2025 | Mar2024 | Mar2023 | Mar2022 | |
|---|---|---|---|---|---|
| Cash Flow from Financing Activities | ₹-2,709 Cr | ₹787 Cr | ₹-3,906 Cr | ₹-77 Cr | ₹-520 Cr |
What is the latest Cash Flow from Financing Activities ratio of GLENMARK PHARMACEUTICALS ?
| Year | Cash Flow from Financing Activities |
|---|---|
| Mar2026 | ₹-2,709 Cr |
| Mar2025 | ₹787 Cr |
| Mar2024 | ₹-3,906 Cr |
| Mar2023 | ₹-77 Cr |
| Mar2022 | ₹-520 Cr |
How is Cash Flow from Financing Activities of GLENMARK PHARMACEUTICALS Trending?
| Years | Cash Flow from Financing Activities | % Change | |
|---|---|---|---|
| Mar2026 | ₹-2,709 Cr | Negative | |
| Mar2025 | ₹787 Cr | Positive | |
| Mar2024 | ₹-3,906 Cr | Negative | |
| Mar2023 | ₹-77 Cr | Negative | |
| Mar2022 | ₹-520 Cr | - | |
Compare Cash Flow from Financing Activities of peers of GLENMARK PHARMACEUTICALS
| Peers & Returns | Market Capitalization | 1 Week | 1 Month | 1 Year | ||
| GLENMARK PHARMACEUTICALS | ₹68,856.8 Cr | 5% | 11.7% | 24.6% | Stock Analytics | |
| SUN PHARMACEUTICAL INDUSTRIES | ₹456,114.0 Cr | NA | -3.9% | 17.3% | Stock Analytics | |
| DIVIS LABORATORIES | ₹239,321.0 Cr | 5% | 21.5% | 44.5% | Stock Analytics | |
| TORRENT PHARMACEUTICALS | ₹185,924.0 Cr | -2.1% | -0.2% | 34.3% | Stock Analytics | |
| CIPLA | ₹113,778.0 Cr | -2% | -2.5% | -8.1% | Stock Analytics | |
| DR REDDYS LABORATORIES | ₹99,025.9 Cr | 0.4% | 4.5% | -4.4% | Stock Analytics | |
GLENMARK PHARMACEUTICALS Share Price vs Sensex
| Share Price Returns(%) | 1 Week | 1 Month | 1 Year |
| GLENMARK PHARMACEUTICALS | 5% |
11.7% |
24.6% |
| SENSEX | 0.7% |
0.8% |
-5.1% |
You may also like the below Video Courses